Cargando…

Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates

OBJECTIVES: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia c...

Descripción completa

Detalles Bibliográficos
Autores principales: Rehm, Susan J., Boucher, Helen, Levine, Donald, Campion, Marilyn, Eisenstein, Barry I., Vigliani, Gloria A., Corey, G.Ralph, Abrutyn, Elias
Formato: Texto
Lenguaje:English
Publicado: Oxford University Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583068/
https://www.ncbi.nlm.nih.gov/pubmed/18782781
http://dx.doi.org/10.1093/jac/dkn372
_version_ 1782160730962788352
author Rehm, Susan J.
Boucher, Helen
Levine, Donald
Campion, Marilyn
Eisenstein, Barry I.
Vigliani, Gloria A.
Corey, G.Ralph
Abrutyn, Elias
author_facet Rehm, Susan J.
Boucher, Helen
Levine, Donald
Campion, Marilyn
Eisenstein, Barry I.
Vigliani, Gloria A.
Corey, G.Ralph
Abrutyn, Elias
author_sort Rehm, Susan J.
collection PubMed
description OBJECTIVES: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia caused by MRSA are generally worse than those observed with methicillin-susceptible S. aureus bacteraemia, clinical characteristics and treatment results in the trial’s pre-specified subset of patients with MRSA were analysed. METHODS: Clinical characteristics and outcomes of patients receiving daptomycin were compared with those receiving vancomycin plus low-dose gentamicin. Success was defined as clinical improvement with clearance of bacteraemia among patients who completed adequate therapy, received no potentially effective non-study antibiotics and had negative blood cultures 6 weeks after end of therapy. RESULTS: Twenty of the 45 (44.4%) daptomycin patients and 14 of the 43 (32.6%) vancomycin/gentamicin patients were successfully treated (difference 11.9%; confidence interval −8.3 to 32.1). Success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided MRSA endocarditis. Cure rates in patients with septic emboli and in patients who received pre-enrolment vancomycin were similar between treatment groups. However, in both treatment groups, success rates were lower in the elderly (≥75 years). Persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, MICs of ≥2 mg/L occurred in five daptomycin and four vancomycin/gentamicin patients. The clinical course of several patients may have been influenced by lack of surgical intervention. CONCLUSIONS: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacteraemia or right-sided endocarditis.
format Text
id pubmed-2583068
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-25830682009-02-25 Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates Rehm, Susan J. Boucher, Helen Levine, Donald Campion, Marilyn Eisenstein, Barry I. Vigliani, Gloria A. Corey, G.Ralph Abrutyn, Elias J Antimicrob Chemother Original Research OBJECTIVES: In a prospective, randomized trial, daptomycin was non-inferior to standard therapy for Staphylococcus aureus bacteraemia and right-sided endocarditis. Since rates of infection due to methicillin-resistant S. aureus (MRSA) infection are increasing and treatment outcomes for bacteraemia caused by MRSA are generally worse than those observed with methicillin-susceptible S. aureus bacteraemia, clinical characteristics and treatment results in the trial’s pre-specified subset of patients with MRSA were analysed. METHODS: Clinical characteristics and outcomes of patients receiving daptomycin were compared with those receiving vancomycin plus low-dose gentamicin. Success was defined as clinical improvement with clearance of bacteraemia among patients who completed adequate therapy, received no potentially effective non-study antibiotics and had negative blood cultures 6 weeks after end of therapy. RESULTS: Twenty of the 45 (44.4%) daptomycin patients and 14 of the 43 (32.6%) vancomycin/gentamicin patients were successfully treated (difference 11.9%; confidence interval −8.3 to 32.1). Success rates for daptomycin versus vancomycin/gentamicin were 45% versus 27% in complicated bacteraemia, 60% versus 45% in uncomplicated bacteraemia and 50% versus 50% in right-sided MRSA endocarditis. Cure rates in patients with septic emboli and in patients who received pre-enrolment vancomycin were similar between treatment groups. However, in both treatment groups, success rates were lower in the elderly (≥75 years). Persisting or relapsing bacteraemia occurred in 27% of daptomycin and 21% of vancomycin/gentamicin patients; among these patients, MICs of ≥2 mg/L occurred in five daptomycin and four vancomycin/gentamicin patients. The clinical course of several patients may have been influenced by lack of surgical intervention. CONCLUSIONS: Daptomycin was an effective alternative to vancomycin/gentamicin for MRSA bacteraemia or right-sided endocarditis. Oxford University Press 2008-12 2008-09-08 /pmc/articles/PMC2583068/ /pubmed/18782781 http://dx.doi.org/10.1093/jac/dkn372 Text en © The Author 2008. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
spellingShingle Original Research
Rehm, Susan J.
Boucher, Helen
Levine, Donald
Campion, Marilyn
Eisenstein, Barry I.
Vigliani, Gloria A.
Corey, G.Ralph
Abrutyn, Elias
Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title_full Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title_fullStr Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title_full_unstemmed Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title_short Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
title_sort daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2583068/
https://www.ncbi.nlm.nih.gov/pubmed/18782781
http://dx.doi.org/10.1093/jac/dkn372
work_keys_str_mv AT rehmsusanj daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT boucherhelen daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT levinedonald daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT campionmarilyn daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT eisensteinbarryi daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT viglianigloriaa daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT coreygralph daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates
AT abrutynelias daptomycinversusvancomycinplusgentamicinfortreatmentofbacteraemiaandendocarditisduetostaphylococcusaureussubsetanalysisofpatientsinfectedwithmethicillinresistantisolates